FDA Approves New HIV Drug, Viread

by Medindia Content Team on  November 23, 2001 at 6:09 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

FDA Approves New HIV Drug, Viread
Biopharmaceutical firm Gilead Sciences Inc. said it has received approval from the US Food and Drug Administration (FDA) to market its antiretroviral agent Viread (tenofovir disoproxil fumarate) for the treatment of HIV in combination with other antiretroviral agents.

Like Viread, such drugs work by blocking the process needed for HIV replication in the body. But Viread is the first nucleotide analogue reverse transcriptase inhibitor to be approved for treatment of HIV in the US. As a result, it may offer a treatment option for patients whose infections have become resistant to currently available medications.

Foster City, California-based Gilead said that the 300 milligram tablet should be available within a few days. The company added that the once-a-day drug would be indicated for use in combination with other antiretroviral agents for the treatment of previously diagnosed patients.

In clinical trials, Viread reduced the level of circulating HIV by about 75%. The most common side effects included nausea, diarrhea, vomiting and flatulence. The drug has demonstrated a significant antiviral response, even in patients who may no longer respond well to available therapies due to the development of viral resistance.


Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive